SAMSUNG PHARM. Co., LTD.

KSE 001360.KS

SAMSUNG PHARM. Co., LTD. Capital Expenditure for the year ending December 31, 2023: USD -9.81 M

SAMSUNG PHARM. Co., LTD. Capital Expenditure is USD -9.81 M for the year ending December 31, 2023, a -309.38% change year over year. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).

SAMSUNG PHARM. Co., LTD. Capital Expenditure for the year ending December 31, 2022 was USD -2.40 M, a 29.54% change year over year.
SAMSUNG PHARM. Co., LTD. Capital Expenditure for the year ending December 31, 2021 was USD -3.40 M, a 48.19% change year over year.
SAMSUNG PHARM. Co., LTD. Capital Expenditure for the year ending December 31, 2020 was USD -6.57 M, a 45.11% change year over year.
SAMSUNG PHARM. Co., LTD. Capital Expenditure for the year ending December 31, 2019 was USD -11.97 M, a -262.47% change year over year.

Key data

Date	Capital Expenditure	Free Cash Flow	Depreciation And Amortization	Deferred Income Tax

KSE: 001360.KS

SAMSUNG PHARM. Co., LTD.

CEO	Mr. Won-Kyu Kim
IPO Date	Jan. 4, 2000
Location	South Korea
Headquarters	35 Jeyakgongdan 2-gil
Employees	240
Sector	Health Care
Industries Pharmaceuticals Drugstores & Retail Pharmacies

Description

SAMSUNG PHARM. Co., LTD. manufactures and sells pharmaceutical products in South Korea. It offers prescription medicines, such as anticancer immunotherapy, antipyretic analgestic and antiinflammatory, antiobesity, hypotensive, antiarteriosclerotic, digestive organs, antophlegms, enzymes, ostepoposis, and transfusion agents, as well as skeletal muscle relaxants, anti-spastic, mixed vitamins, antibiotics, and others. The company also provides medicines for digestive system, medicines for liver disorder, medicines for circulation system, cold medicines, nutritional supplements, health tonics, and others, as well as vitamins and energy drinks, and functional foods. The company was founded in 1929 and is based in Hwaseong-si, South Korea.

Key trends

Past 5 years